Neoadjuvant immunotherapy is expanding treatment options in CSCC by shrinking complex tumors, improving surgical outcomes, ...

There’s an ongoing uncertainty among experts about whether neoadjuvant therapy or surgery first is best for patients with ...

Three-fourths of patients had cancer-free mediastinal lymph nodes, clear surgical margins ...

Mastectomy did not significantly improve survival for younger women with high-risk locoregionally advanced breast cancer, ...

The extent of residual prostate cancer in the surgical specimen following intensified neoadjuvant therapy for high-risk localized prostate cancer may predict metastatic recurrence. Residual disease ...

Oncologists are increasingly reaching for the prescription pad before the scalpel, driving a dramatic rise in the use of neoadjuvant therapy for solid tumors, according to new research. The second ...

Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Omission of Radiotherapy or Not? The following represents disclosure information provided by authors of this manuscript. All relationships are ...

Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147) Neoadjuvant approaches for HER2-positive breast cancer continue ...

The future of systemic therapy for cutaneous squamous cell carcinoma (CSCC) is rapidly evolving, with research focused on ...

Neoadjuvant mitomycin C showed a favorable safety profile with mild to moderate side effects, including hematuria, dysuria, and itchy scalp. The trial did not show significant improvement in 12-month ...